Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to share the findings of two publications in the American Journal of Transplantation that demonstrate how the company's TNX-1500 monoclonal antibody product candidate aided in the prevention of organ rejection for kidney and heart transplants.

Lederman says these animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. He adds that Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com